Anaplastic thyroid cancer, tumorigenesis and therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453–464. doi: 10.1245/ASO.2006.05.042
Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715–726. doi: 10.1089/thy.1998.8.715
Albores-Saavedra J, Henson DE, Glazer E et al (2007) Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 18:1–7. doi: 10.1007/s12022-007-0002-z
Kobayashi TK, Asakawa H, Umeshita K et al (1996) Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 18:36–41. doi: 10.1002/(SICI)1097-0347(199601/02)18:1<36::AID-HED5>3.0.CO;2-#
Kim TY, Kim KW, Jung TS et al (2007) Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 29:765–772. doi: 10.1002/hed.20578
Sugitani I, Kasai N, Fujimoto Y et al (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622. doi: 10.1007/s002680020166
Delellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94:662–669. doi: 10.1002/jso.20700
Saltman B, Singh B, Hedvat CV et al (2006) Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 140:899–905. doi: 10.1016/j.surg.2006.07.027
Wiseman SM, Loree TR, Rigual NR et al (2003) Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662–670. doi: 10.1002/hed.10277
Wiseman SM, Masoudi H, Niblock P et al (2007) Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14:719–729. doi: 10.1245/s10434-006-9178-6
Wiseman SM, Griffith OL, Deen S et al (2007) Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 142:727–729
Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404. doi: 10.1210/jc.2003-030838
Lemoine NR, Mayall ES, Wyllie FS et al (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159–164
Quiros RM, Ding HG, Gattuso P et al (2005) Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103:2261–2268. doi: 10.1002/cncr.21073
Segev DL, Umbricht C, Zeiger MA (2003) Molecular pathogenesis of thyroid cancer. Surg Oncol 12:69–90. doi: 10.1016/S0960-7404(03)00037-9
Lam KY, Lo CY, Chan KW et al (2000) Insular and anaplastic carcinoma of the thyroid. A 45 year comparative study at a single institution and review of the significance of p53 and p21. Ann Surg 231:329–338. doi: 10.1097/00000658-200003000-00005
Moretti F, Nanni S, Farsetti A et al (2000) Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 85:302–308. doi: 10.1210/jc.85.1.302
LaPerle KM, Jhiang SM, Capen CC (2000) Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671–677
Nakashima M, Takamura N, Namba H et al (2007) RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high grade malignancy. Hum Pathol 38:621–628. doi: 10.1016/j.humpath.2006.10.013
Santoro M, Papotti M, Chiappetta G et al (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–379. doi: 10.1210/jc.87.1.370
Shannon KB, Salmon ED (2002) Chromosome dynamics: new light on Aurora B kinase function. Curr Biol 12:458–460. doi: 10.1016/S0960-9822(02)00945-4
Ulisse S, Delcros JG, Baldini E et al (2006) Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 119:275–282. doi: 10.1002/ijc.21842
Sorrentino R, Libertini S, Pallante PL et al (2005) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928–935. doi: 10.1210/jc.2004-1518
Lim SC, Lee MS (2002) Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 9:915–928
Barton MC, Akli S, Keyomarsi K (2006) Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol 209:686–694. doi: 10.1002/jcp.20818
Musgrove EA (2006) Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24:13–19. doi: 10.1080/08977190500361812
Fagin JA, Matsuo K, Karmakar A et al (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179–184. doi: 10.1172/JCI116168
Garcia-Rostan G, Tallini G, Herrero A et al (1999) Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811–1815
Wiseman SM, Masoudi H, Niblock P et al (2006) Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 191:581–587. doi: 10.1016/j.amjsurg.2006.02.005
Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J et al (2003) E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580–587. doi: 10.1046/j.1365-2559.2003.01642.x
Garcia-Rostan G, Camp RL, Herrero A et al (2001) Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987–996
Hou P, Liu D, Shan Y et al (2007) Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161–1170. doi: 10.1158/1078-0432.CCR-06-1125
Garcia-Rostan G, Costa AM, Pereira-Castro I et al (2005) Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199–10207. doi: 10.1158/0008-5472.CAN-04-4259
Ensinger C, Spizzo G, Moser P et al (2004) Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann NY Acad Sci 1030:69–77. doi: 10.1196/annals.1329.009
Viglietto G, Maglione D, Rambaldi M et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579
Prichard CN, Kim S, Yazici YD et al (2007) Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117:674–679. doi: 10.1097/MLG.0b013e318031055e
Kim S, Prichard CN, Younes MN et al (2006) Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12:600–607. doi: 10.1158/1078-0432.CCR-05-1325
Kim S, Schiff BA, Yigitbasi OG et al (2005) Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4:632–640. doi: 10.1158/1535-7163.MCT-04-0293
Hoffman S, Burchert A, Wunderlich A et al (2007) Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 31:105–113. doi: 10.1007/s12020-007-0008-9
Yohoi K, Thaker PH, Yazici S et al (2005) Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 65:3716–3725. doi: 10.1158/0008-5472.CAN-04-3700
Kim S, Yazici YD, Calzada G et al (2007) Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6:1785–1792. doi: 10.1158/1535-7163.MCT-06-0595
Smit JW, Schroder-van der Elst JP, Karperien M et al (2007) Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 87:1247–1253. doi: 10.1210/jc.87.3.1247
Hsieh YJ, Ke CC, Liu RS et al (2007) Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter. Anticancer Res 27:2515–2522
Lee YJ, Chung JK, Shin JH et al (2004) In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 14:889–895. doi: 10.1089/thy.2004.14.889
Jeong H, Kim YR, Kim KN et al (2006) Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol 33:875–882. doi: 10.1016/j.nucmedbio.2006.07.004
Presta I, Arturi F, Ferretti E et al (2005) Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer 5:80. doi: 10.1186/1471-2407-5-80
Sugawara I, Masunaga A, Itoyama S et al (1995) Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett 95:135–138. doi: 10.1016/0304-3835(95)03878-z
Yasuhisa K, Shin-ya M, Michinori M et al (2007) Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303–1310. doi: 10.1111/j.1349-7006.2007.00538.x
Touhey S, O’Connor R, Plunkett S et al (2002) Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition: identification of novel chemotherapeutic drug resistance modulators. Eur J Cancer 38:1661–1670. doi: 10.1016/S0959-8049(02)00128-4
Brignardello E, Gallo M, Baldi I et al (2007) Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156:425–430. doi: 10.1530/EJE-06-0677
Kebebew E, Greenspan FS, Clark OH et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330–1335. doi: 10.1002/cncr.20936
Pierie JP, Muzikansky A, Gaz RD et al (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57–64. doi: 10.1245/aso.2002.9.1.57
Lang BH, Lo CY (2007) Surgical options in undifferentiated thyroid carcinoma. World J Surg 31:969–977. doi: 10.1007/s00268-007-0776-7